[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-337641-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-337641-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","identification-of-an-anaplastic-subtype-of-prostate-cancer-amenable-to-therapies-targeting-sp1-or-translation-elongation","Identification of an anaplastic subtype of prostate cancer amenable to therapies targeting SP1 or translation elongation","","Histopathological heterogeneity characterizes prostate cancer, yet mechanisms defining aggressive castration-resistant behavior remain unclear. Using spatial and parallel single-nucleus transcriptomics, the study identifies an androgen receptor–positive but neuroendocrine-null primary subtype with morphologic and molecular traits of small cell carcinoma. Small cell–like prostate cancer shows low AR with high stemness and proliferation. The work highlights protein translation and SP1 as therapeutic drivers of this AR-indifferent castration-resistant phenotype. An SP1 inhibitor, plicamycin, suppresses growth in vivo, and the FDA-approved translation elongation inhibitor homoharringtonine impedes progression in models and patients, enabling an SCLPC-specific drug-selectivity signature.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/identification-of-an-anaplastic-subtype-of-prostate-cancer-amenable-to-therapies-targeting-sp1-or-translation-elongation/337641/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/identification-of-an-anaplastic-subtype-of-prostate-cancer-amenable-to-therapies-targeting-sp1-or-translation-elongation/337641.png","ImageObject",300,407,{"name":42,"@type":43},"Ava Thompson","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-08","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What subtype of prostate cancer is identified in the study?","Question",{"text":63,"@type":64},"The study reports an androgen receptor–positive but neuroendocrine-null primary subtype with small cell carcinoma-like morphologic and molecular characteristics, termed small cell–like prostate cancer (SCLPC).","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Why are SP1 and protein translation considered therapeutic targets?",{"text":68,"@type":64},"Molecular characterization prioritizes protein translation, with up-regulated ribosomal protein genes, and identifies SP1 as a transcription factor driving the SCLPC phenotype and overexpressed in castration-resistant prostate cancer.",{"name":70,"@type":61,"acceptedAnswer":71},"How do plicamycin and homoharringtonine affect castration-resistant disease?",{"text":72,"@type":64},"Plicamycin, an SP1-specific inhibitor, suppresses castration-resistant prostate cancer growth in vivo, while homoharringtonine, a translation elongation inhibitor, impedes progression in preclinical models and in patients with castration-resistant prostate cancer.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},337641,1790169120,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":128,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},1649267921044,"https://us-avatar.wpscdn.com/avatar/1800007509477c92dfb?_k=1786009248482753345","CANCER  \nIdentification of an anaplastic subtype of prostate cancer amenable to therapies targeting SP1 or translation elongation  \nCheng Zou1,2,3†, Wenchao Li4†, Yuanzhen Zhang1,2,3†, Ninghan Feng5†, Saisai Chen4, Lianlian Yan1, Qinju He1,2, Kai Wang4, Wenjun Li1,3, Yingying Li1,3, Yang Wang5, Bin Xu4,6*, Dingxiao Zhang1,2,3*  \nHistopathological heterogeneity is a hallmark of prostate cancer (PCa). Using spatial and parallel single-nucleus transcriptomics, we report an androgen receptor (AR)–positive but neuroendocrine-null primary PCa subtype with morphologic and molecular characteristics of small cell carcinoma. Such small cell–like PCa (SCLPC) is clinically aggressive with low AR, but high stemness and proliferation, activity. Molecular characterization prioritizes protein translation, represented by up-regulation of many ribosomal protein genes, and SP1, a transcriptional factor that drives SCLPC phenotype and overexpresses in castration-resistant PCa (CRPC), as two potential therapeutic targets in AR-indifferent CRPC. An SP1-specific inhibitor, plicamycin, effectively suppresses CRPC growth in vivo. Homoharringtonine, a Food And Drug Administration–approved translation elongation inhibitor, impedes CRPC progression in preclinical models and patients with CRPC. We construct an SCLPC-specific signature capable of stratifying patients for drug selectivity. Our studies reveal the existence of SCLPC in admixed PCa pathology, which may mediate tumor relapse, and establish SP1 and translation elongation as actionable therapeutic targets for CRPC.  \ncopyright © 2024 the Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. no claim to original U.S.  \nGovernment Works. distributed under a creative commons Attribution noncommercial license 4.0 (cc BY-nc) .  \nINTRODUCTION  \nProstate cancer (PCa) is the second most frequent cancer and the fifth leading cause of cancer death among men worldwide (1). The prostate is an androgen-sensitive organ demonstrating an organized glandular epithelium with a well-structured bilayer of basal and luminal cells (LCs) (2). Androgen deprivation therapy (ADT) is the main management strategy for PCa. However, most treated patients invariably develop castration-resistant PCa (CRPC), currently a lethal form of the disease. Second-generation antiandrogens (e.g., enzalutamide andabiraterone) thus have been developed for CRPC by further inhibition of the androgen receptor (AR) pathway (3). Unfortunately, most patients with CRPC still fail to achieve durable responses to these AR inhibitors, resulting in rapid recurrence and eventually patient death. Mechanisms underlying CRPC development and maintenance remain poorly understood.  \nPCa displays substantial clinical, pathologic, and molecular heterogeneity. Studies have therefore documented that castration resistance can originate from both intrinsic [e.g., preexisting androgen-independent cancer clones (2)] and adapted [e.g., transcriptomic and metabolic reprogramming (3)] mechanisms. At the macroanatomical level, the majority of untreated primary PCa (pri-PCa) present as AR+ acinaradenocarcinomas (Adeno), but aggressive variants of advanced PCa  \n1the Affiliated Xiangtan central hospital of hunan University, School of Biomedical Sciences, hunan University, changsha 410082, hunan Province, china. 2hunan Key laboratory of Animal Models and Molecular Medicine, hunan University, changsha 410082, hunan Province, china. 3Shenzhen Research institute, hunan University, Shenzhen 518000, china. 4department of Urology, School of Medicine, Affiliated Zhongda hospital of Southeast University, nanjing 210009, Jiangsu Province, china. 5department of Urology and Wuxi School of Medicine, Jiangnan University Medical center, Wuxi 214002, Jiangsu Province, china. 6national Medicine-engineering interdisciplinary industry-education integration innovation Platform (Ministry of education), Basic Medicine Research and innovation cent","cbCaijxWvZzI5RvV","https://ap.wps.com/l/cbCaijxWvZzI5RvV","pdf",3456037,"English","# Introduction\n## Prostate cancer burden and treatment limitations\n## Castration-resistant mechanisms and clinical heterogeneity\n## Aggressive prostate cancer variants and intratumoral mixtures\n## Single-cell RNA sequencing and spatial transcriptomics overview","[{\"question\":\"What subtype of prostate cancer is identified in the study?\",\"answer\":\"The study reports an androgen receptor–positive but neuroendocrine-null primary subtype with small cell carcinoma-like morphologic and molecular characteristics, termed small cell–like prostate cancer (SCLPC).\"},{\"question\":\"Why are SP1 and protein translation considered therapeutic targets?\",\"answer\":\"Molecular characterization prioritizes protein translation, with up-regulated ribosomal protein genes, and identifies SP1 as a transcription factor driving the SCLPC phenotype and overexpressed in castration-resistant prostate cancer.\"},{\"question\":\"How do plicamycin and homoharringtonine affect castration-resistant disease?\",\"answer\":\"Plicamycin, an SP1-specific inhibitor, suppresses castration-resistant prostate cancer growth in vivo, while homoharringtonine, a translation elongation inhibitor, impedes progression in preclinical models and in patients with castration-resistant prostate cancer.\"}]","Identification of an anaplastic subtype of prostate cancer amenable to therapies targeting SP1 or translation elongation | PDF",1790019961,48,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ff32a81ec1bb8fae81b403975243d359.webp",983,1250,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6ade385af712573f3276179df63674cf.webp",982,1249,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cf62790c12c58b857415912abcd9a283.webp",981,1248,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fb339f24011d91050dee9406ce9e28ff.webp",980,1247]